Marshall Wace’s Harmony Biosciences HRMY Stock Holding History

Marshall Wace’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.19M	Buy	149,715 +120,281	+409%	+$3.94M	﹤0.01%	1385
2025 Q4	$1.1M	Sell	29,434 -255,884	-90%	-$8.41M	﹤0.01%	1877
2025 Q3	$7.86M	Sell	285,318 -924,166	-76%	-$31.8M	0.01%	1008
2025 Q2	$38.2M	Buy	1,209,484 +321,947	+36%	+$10.4M	0.04%	366
2025 Q1	$29.5M	Sell	887,537 -42,207	-5%	-$1.51M	0.04%	411
2024 Q4	$32M	Buy	929,744 +579,103	+165%	+$19.9M	0.04%	402
2024 Q3	$14M	Buy	350,641 +45,029	+15%	+$1.58M	0.02%	634
2024 Q2	$9.22M	Buy	305,612 +181,092	+145%	+$5.45M	0.01%	769
2024 Q1	$4.18M	Buy	+124,520	New	+$4M	0.01%	1068
2023 Q1	–	Sell	-162,906	Closed	-$8.98M	–	2853
2022 Q4	$8.98M	Buy	162,906 +141,571	+664%	+$7.78M	0.02%	863
2022 Q3	$944K	Buy	+21,335	New	+$1.04M	﹤0.01%	2439
2022 Q2	–	Sell	-83,961	Closed	-$4.09M	–	3608
2022 Q1	$4.09M	Buy	83,961 +34,974	+71%	+$1.43M	0.01%	1527
2021 Q4	$2.09M	Buy	48,987 +34,098	+229%	+$1.36M	﹤0.01%	2011
2021 Q3	$570K	Buy	+14,889	New	+$479K	﹤0.01%	2321
2021 Q2	–	Sell	-15,545	Closed	-$514K	–	2820
2021 Q1	$514K	Buy	+15,545	New	+$545K	﹤0.01%	1928

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace's HRMY Position: Q1 2026 in Review

Marshall Wace increased its Harmony Biosciences (HRMY) stake by 409% in Q1 2026, buying an estimated $3.94M and bringing the position to 149,715 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Marshall Wace first reported a position in HRMY in Q1 2021 and has held it in 15 quarters since. The position peaked at $38.2M in Q2 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Marshall Wace held 149,715 shares of Harmony Biosciences worth $4.19M as of Q1 2026.
Marshall Wace bought 120,281 Harmony Biosciences shares in Q1 2026, an estimated $3.94M.
Harmony Biosciences made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1385 holding.
Marshall Wace first reported a position in Harmony Biosciences in Q1 2021 and has held it in 15 quarters since.
Marshall Wace's Harmony Biosciences position peaked at $38.2M in Q2 2025.
309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.